Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832140 | 0.89 | POLB (0.42) | SMN1; SMN2LMNAKMT2AMEN1HPGD | |
| SCHEMBL24135396 | 0.83 | CHRM2 (0.44) | SMN1; SMN2NPC1LMNAKMT2AMEN1 | |
| SCHEMBL15832155 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1LMNAKMT2AMEN1 | |
| SCHEMBL15832143 | 0.73 | PPID (0.47) | HPGDALDH1A1 | |
| SCHEMBL15832163 | 0.73 | HPGD (0.41) | SMN1; SMN2LMNAKMT2AMEN1HPGD | |
| SCHEMBL17335992 | 0.73 | CYP3A4 (0.63) | SMN1; SMN2NPC1LMNAKMT2AMEN1 | |
| SCHEMBL10048212 | 0.73 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1LMNAKMT2AMEN1 | |
| SCHEMBL23747455 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1LMNAKMT2AMEN1 | |
| SCHEMBL13369666 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1LMNAKMT2AMEN1 | |
| SCHEMBL15832154 | 0.71 | SUCNR1 (0.39) | SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | SMN1; SMN2 2177/4885NPC1 723/4885LMNA 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.